California rolls out low-cost insulin label amid slow market uptake

Governor Gavin Newsom's CalRx initiative, a state-branded generic insulin, has moved more than 120,000 five-pen packs of insulin glargine priced at $55 each, a steep discount from the $89-$411 range of brand products. Created via a $50 million contract with Utah-based nonprofit Civica, the biosimilar aims to serve uninsured Californians and challenge the dominance of Eli Lilly, Sanofi and Novo Nordisk. Despite statewide distribution through major wholesalers and availability at retailers like Walgreens, CVS and Costco, uptake is slow; many pharmacists only recently discovered the product and have yet to dispense it.

CalRx is one element of a larger state strategy that includes free naloxone, school-based albuterol inhalers, and upcoming generic epinephrine and TB drugs, with plans to add GLP-1 medications before Newsom leaves office. Health policy experts argue the effort is symbolic, benefiting a limited number of drugs and patients, while industry groups contend that existing discount mechanisms already lower out-of-pocket costs. Nonetheless, the program reflects growing political focus on curbing prescription-drug prices nationwide.